Array discontinues ovarian cancer Phase III

Array BioPharma Inc. (NASDAQ:ARRY) said it will discontinue the Phase III MILO study of binimetinib ( MEK162) to treat low-grade serous ovarian cancer after an interim analysis of the progression free survival primary endpoint "crossed the predefined futility boundary."

The company said its decision will not affect the Phase III NEMO or COLUMBUS studies of binimetinib to treat melanoma. Binimetinib met NEMO's primary endpoint in December, improving progression-free survival (PFS) in patients with neuroblastoma Ras viral (v-Ras) oncogene (NRAS)-mutant melanoma. Array expects to submit an NDA in the indication this half (see BioCentury Extra, Dec. 16, 2015). ...